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Abstract 
The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on 
AHA) are to enable European citizens to lead healthy, active and independent lives while ageing. The 
EIP on AHA includes 74 Reference Sites. The aim of this study is to transfer innovation from an App 
developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference 
sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly 
will be compared using validated information and communication technology (ICT) tools (i.e. the 
Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or 
regions across Europe. This will improve understanding, assessment of burden, diagnosis and 
management of rhinitis in the elderly by comparison with an adult population. Specific objectives 
will: (i) assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) study 
phenotypic characteristics and treatment over a period of one year of rhinitis and asthma 
multimorbidity at baseline (cross-sectional study) and (iii) follow-up using visual analogue scale 
(VAS). This part of the study may provide some insight into the differences between the elderly and 
adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined 
in adults.   
Key words 
European Innovation Partnership on Active and Healthy Ageing, allergy, asthma, rhinitis, Allergy 
Diary, CARAT 
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AHA: Active and Healthy Aging 
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AR: allergic rhinitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
CARAT: Control of Allergic Rhinitis and Asthma Test 
EIP: European Innovation Partnership 
EU: European Union 
HIT: Health information technology  
ICT: information and communications technology 
MACVIA: Contre les MAladies Chroniques pour un VIellissement Actif  
MASK: MACVIA-ARIA Sentinel NetworK 
NAR: non allergic rhinitis 
SCUAD: Severe chronic upper airways disease 
VAS: visual analogue scale 
 
Funding: Unrestricted educational grant from Meda (Bad Homburg, Germany). Structural 
Development Funds from the European Union (Région Languedoc Roussillon). The App belongs to 
the Région Occitanie (formerly Languedoc-Roussillon, Midi-Pyrénées, France). MASK is a project of 
the B3 Action Plan of the European Innovation Partnership on Active and Healthy Ageing - EIP on 
AHA (European Commission DG Santé and DG CONNECT) and of the “Twinning” (Transfer of 
Innovation, 2016 Pilot Twinning Support Scheme of the EIP on AHA) of the App in 22 EIP on AHA 
Reference Sites. 
 
 
Introduction 
Rhinitis, the most common chronic disease in Europe, often starts early in life, persists across the life 
cycle and causes a high disease burden in all age groups (1). Rhinitis and asthma multimorbidity is 
common (1) and the two diseases should be considered jointly. The symptoms of allergic rhinitis 
(AR) can cause considerable morbidity in terms of physical and emotional comfort and functional 
capacity. Work productivity is one of the major societal impacts of AR (2, 3). Sleep impairment is 
common in AR (4, 5) and is associated with severe nasal symptoms (6). 
By 2020, rhinitis will affect at least 20% of the old age population (7-11). Rhinitis in this age group 
has phenotypic specificities and treatment modalities including poly-medication. The effects of 
polypharmacy may contribute to congestion and dryness (12). Sex may also be a confounding factor 
in the elderly. Phenotypic characteristics and treatment of rhinitis in the elderly depend on ageing 
(physiology, immunology), socio-cultural barriers, environmental factors (urban versus rural), allergic 
and non-allergic multi-morbidities (13, 14), drug availability and affordability, specific side effects to 
drugs in this age group (15), health systems as well as type of care. However, rhinitis burden in the 
elderly is an under-recognized and under-treated problem (8). Important demographic changes are 
expected in the European population. It is therefore crucial to study the phenotype and treatment of 
rhinitis-asthma multimorbidity in this age group in different European regions in order to (i) provide 
new concepts and hypotheses and (ii) offer new diagnosis and management strategies to reduce health 
and social inequalities. 
Measures of AR control include symptom scores, control scores and patients’ self-administered 
Visual Analogue Scales (VAS) (11, 16-23). VAS, a psychometric response scale for subjective 
characteristics or attitudes, has been successfully used in many diseases including AR. Severe 
Chronic Upper Airway Disease (SCUAD) defines uncontrolled AR patients despite optimal 
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pharmacotherapy (24). The Control of Allergic Rhinitis and Asthma Test (CARAT) (25-28) is the 
only self-administered questionnaire to quantify the control of both AR and asthma concurrently. It 
consists of 10 questions on upper and lower airway symptoms, sleep interference, activity limitation, 
and the need to increase medication over a four-week period. CARAT meets all items of the 
COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) 
checklist (29-31). CARAT was developed and validated in Portugal and has been translated and 
culturally adapted in over 25 languages and nine countries (Belgium, Brazil, France, Germany, 
Greece, India, Italy, The Netherlands and Ukraine). Web and smartphone versions have been 
developed, and an open model of distribution contributes to its dissemination. 
European Innovation Partnerships (EIPs) bring together all relevant actors at European Union (EU), 
national and regional levels in order to: (i) step up research and development efforts; (ii) coordinate 
investments in demonstration and pilots; (iii) anticipate and fast track any necessary regulation and 
standards; and (iv) ensure that any breakthroughs are quickly brought to the market. The goals of the 
European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable 
European citizens to lead healthy, active and independent lives while ageing. The EIP on AHA 
includes 74 Reference Sites. 
MACVIA-France (Fighting chronic diseases for active and healthy ageing in France) is a reference 
site of the EIP on AHA (32, 33). It initiated the project “Integrated Care Pathways for airway diseases 
(AIRWAYS ICPs)” (34, 35). AIRWAYS ICPs aims to develop multi-sectoral ICPs for rhinitis and its 
multi-morbidities in the elderly, implementing emerging technologies for individualised and 
predictive medicine (35). A patient-centred mobile application (App for iOS and Android 
smartphones) has been developed (6, 36). This App (Allergy Diary) uses VAS scores and allows the 
daily assessment of rhinitis and asthma control by patients themselves (37, 38). It will also include a 
Clinical Decision Support System (CDSS) (22). The Allergy Diary is available for free download in 
21 countries and 16 languages and has already been tested by over 8,000 users of all ages. Real time 
data from users’ smartphones can be stored and retrieved in a functional database. This EIP on AHA 
Synergy project has been developed between Action Groups of the EIP on AHA to build bridges for 
innovation in AHA (39). The Allergy Diary also includes CARAT. 
Regional organisations engaged in the EIP on AHA were proposed to apply for a grant in order to 
facilitate the transfer of innovative practices (Twinning) for implementation in other regions 
(http://www.scale-aha.eu/news.html). The aim of this initiative is to facilitate the deployment of large-
scale digitally-enabled innovative solutions for health and care delivery to the ageing population. It 
therefore contributes to the European Scaling Up Strategy of the EIP on AHA, already initiated by 
MACVIA-ARIA (40). 
1- Objectives of the MACVIA-ARIA Twinning 
The transfer of innovative practices (Twinning) aims to transfer and implement (i) the Allergy Diary 
developed by MACVIA-LR (37, 38) and (ii) CARAT (25-28) to the different EIP on AHA Reference 
Sites. Other tools may also be used. 
 
The longer-term aim of the Twinning is (i) to provide care pathways for individualized and predictive 
medicine for rhinitis and asthma multimorbidity in the elderly (36), (ii) to extend the study to sleep 
impairment in AR and asthma and (iii) to assess interactions of allergen exposure and air pollution. 
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Moreover, the Twinning will allow Reference Sites from different areas of Europe to interact. This 
will increase knowledge, enable the transfer of know-how and support the establishment of local 
structured thematic networks on respiratory diseases sharing tools, indicators and knowledge that are 
available in the EU context.  
Although the vast majority of Reference Sites will work on the main aim of the Twinning (rhinitis and 
asthma multimorbidity in the elderly), some will have a different Twinning process to reinforce the 
project (Table 2).  
Since the study will last one year - to account for differences in allergen exposure - the starting data is 
not necessarily the same in all countries and new Reference Sites can join the Twinning within the 
next six months. 
2- Originator and adopter organisations 
There are two types of organizations involved (Table 3): 
• The "Organization transferring the innovative practice" (originator organization): the organization 
with the experience and know-how developed in a particular field of intervention, awarded 
Reference Site status in the 2016 call and included in the innovative practices repository of the EIP 
on AHA (https://ec.europa.eu/eip/ageing/repository_en). 
• The "Organization adopting the innovative practice” (receiving/adopter organization): the 
organization that will receive the innovative practice and deploy / implement it in its territory. This 
is the organization that was awarded Reference Site status in the 2016 call and that will benefit from 
the experience and know-how developed by the "organization transferring an innovative practice" in 
a particular field of intervention. 
There will also be Reference Sites that will help to perform the Twinning. The MACVIA-ARIA 
Twinning mainly includes Reference Sites certain other sites are also included (Figure 1).  
 
All Reference Sites wishing to join the MACVIA-ARIA Twinning at a later stage are welcome. 
In France, Italy, Germany, Lithuania, Poland, Portugal and Turkey, the Twinning will be done at a 
national level with the Allergy Society and national health authorities of the country. 
Twinning in the entire country 
 
3- MACVIA-ARIA Twinning methodology 
3-1- Tools 
The Allergy Diary will be used in all centres except for Andalucia. It is currently available on cell 
phones and also on tablets for health care professionals in English (termed Allergy Diary Companion) 
(37, 38). Translations are pending. It includes EQ-5D (46), the WPAI-AS questionnaire (47-49) and, 
in some countries, CARAT (26, 28, 50)  (when available in electronic form). 
3-1-1- Allergy Diary 
3-1-1-1- App (ANDROID and IOS) 
The Allergy Diary collects information on AR symptoms experienced (nasal and ocular), disease type 
(intermittent/persistent), how symptoms impact users’ lives, and type(s) of AR treatment used (Table  
1 Online supplement 1) (6).  
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Geolocalized users assess their daily symptom control using the touchscreen functionality on their 
smart phone to click on five consecutive VAS (i.e. general, nasal and ocular symptoms, asthma and 
work) (Online supplement 2).  
Medications are also recorded daily (Online supplement 3). Mobile phone messaging facilitates the 
management of AR, providing prompts to assess disease control, take medication, and visit a health 
care provider if appropriate.  
The system was initially deployed in 15 European countries and in 15 languages (translated and back-
translated, culturally adapted and legally compliant). It is now also available in Australia, Brazil, 
Canada, Mexico, Switzerland and Turkey. The system is currently being prepared for the Czech 
Republic. 
Several observational studies have been carried out using the Allergy Diary. 
 The Allergy Diary (Android and iOS) is user friendly and has been tested for AR and 
conjunctivitis in over 5,000 users. The simple baseline questionnaire administered by cell phones 
allows the identification of phenotypic differences between a priori defined rhinitis and asthma 
multimorbidity groups and proposes novel concepts on AR (6). 
 The VAS reporting has been validated (Caimmi et al, submitted). 
 Work productivity can be assessed daily (VAS) and there is a highly significant correlation 
between rhinitis control and work (39). 
 A cross-sectional observational study enables the differentiation of treatment strategies in AR 
(Bousquet et al, in preparation). 
 Over 5% of Allergy Diary users are ≥65 yrs of age.  
Outcomes 
In this observational study, all subjects will fill in the following:  
 Baseline characteristics (Table 5).  
 EQ5D (46) which can be used in the elderly.  
 Treatments (Online supplement 3).  
 Four consecutive VAS measurements (general, nasal and ocular symptoms, asthma) (Online 
supplement 2). 
In addition, adults will fill in: 
 The Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) (47, 
51) (Online supplement 4).   
 VAS for work (Online supplement 2). 
3-1-1-2- Printing of App data using a computer 
Patients cannot give access of their electronic data to a HCP due to privacy policies. However, they 
can print the daily control of their disease as well as their medication details that they filled in in the 
Allergy Diary. The procedure is as follows (Figure 2): 
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3-1-2- CARAT   
CARAT will be implemented in the Allergy Diary app for European countries with completed cultural 
adaptation processes (The Netherlands, Belgium, Germany, Greece, Ukraine, Italy, France). Every 
two to four weeks, participants with rhinitis and asthma will be prompted to fill in the CARAT 
questionnaire. 
3-1-3- The physician’s questionnaire 
For some patients, physicians will fill in a questionnaire that includes the questions of the Allergy 
Diary and of CARAT (Table 4). 
The questionnaire will be filled in directly using the ARIA website. 
3-2- Ethics 
The terms of use have been translated into all languages and customized according to the country’s 
legislation. They allow the use of the results for research purposes. The example of the UK terms of 
use is given in Online supplement 5 (39). The data are anonymised except for the geolocalized data 
that are never totally anonymous. The European Commission's Article 29 Working Party stated that 
geolocation information is personal data (http://ec.europa.eu/newsroom/just/item-
detail.cfm?item_id=50083) and that information can only be collected, shared, or stored with people's 
express consent. This is the case for MASK since users agree on geolocation in the terms of use of the 
App. Moreover, geolocation is optional and the user can allow it or not on his/her cell phone., 
Geolocation can be removed at any time.  The problem of privacy due to geolocation was examined 
by the lawyers of each of the countries in which MASK has been launched and it was found to be in 
accordance with the existing laws. Moreover, geolocation is not used in the data mining process 
neither is the phone IP. 
The Allergy Diary is a CE1 medical device and does not require ethical approval. An ethical 
agreement has been approved by a German ethics committee for the questionnaire. This ethical 
agreement will serve for all EU countries. 
A participation agremeent to be signed by the patient has been proposed. 
3-3- Possible biases 
As in any other observational study, the absence of randomization may be a source of relevant biases 
(52). However, observational studies reflect “real world” use and practice more closely than 
randomized control trials (RCTs) in terms of the heterogeneous patient populations included and 
medical interventions (53). They can provide clinically relevant information not necessarily provided 
by RCTs. Given the limitations of an observational study approach, it is important to optimize their 
study design to maximize their validity. In particular, known causes of bias and confounding should 
be measured (53).  
 
However, this initiative was not designed to compare questionnaires with apps. A bias might be 
introduced because app users provide self-reported information in an uncontrolled setting. However, a 
recent systematic review has assessed the impact that smartphone and tablet apps as a delivery mode 
have on the quality of survey questionnaire responses compared to any other traditional alternative 
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delivery mode. The review showed that apps might not affect data equivalence as long as the intended 
clinical application of the survey questionnaire, its intended frequency of administration and the 
setting in which it was validated remain unchanged (54). 
3-4- Timeframe for procurement / implementation until 2018 
 The adopters will use freely available existing tools including (i) the Allergy Diary (Apple App 
Store and Google Play Store) and (ii) the questionnaire filled in by physicians.  
 The Allergy Diary is available in 21 countries (Austria, Australia, Belgium, Brazil, Canada, 
Denmark, Finland, France, Germany, Greece, Italy, Lithuania, Mexico, Netherlands, Poland, 
Portugal, Spain, Sweden, Switzerland, Turkey and UK) and languages (national languages plus 
Catalan and Finnish Swedish). It can be implemented immediately. For other countries, 
translation, back-translation, cultural adaptation and legal compliance all need approximately 3 to 
6 months. 
 The phenotype, EQ-5D (MAFEIP (39, 55)) and AR/asthma medication lists (IMS list customized 
for each country) are included in the Allergy Diary.  
 
3-5- Action/implementation plan  
Three protocols can be implemented (Table 5). 
1- Deployment of the App to the different Reference Sites (RS): Immediate and free access 
(Apple App Store and Google Play Store) is available for 21 countries. From 3 to 6 months for 
other countries. 
2- Centres participating in the Twinning 
Each Reference Site will select physicians (with training in allergy) who work in out-patient clinics, 
in hospitals and/or in private practice. A combination of both practices would be optimal. All 
physicians will be volunteers for the study. There will be no compensation. 
3- Enrolment of users (the elderly) with rhinitis  
If possible, each Reference Site will enrol 50 elderly persons (≥65 yrs) able to use the Allergy Diary 
and 100 adults (<65 yrs) using the longer protocol. If possible, the number of users will be increased. 
At the end of the year, each reference site will receive an overview of the data collected in its site. 
Each physician is expected to enrol at least 10 adults and 5 old age persons. 
The duration of enrolment is 12 months to account for variability in allergen exposure during a year. 
Thus, the study can be initiated in Reference Sites from January 1, 2017 to July 1, 2017. 
4- Study protocol:  
Two different protocols can be used (and probably mixed in the same region) depending on the 
decision of the physician. 
 Protocol 1: The physician enrolling the user asks the patient to use the Allergy Diary and check 
that this is done and that the user has agreed to be geolocalised. This latter point is of importance 
since it will help to analyse differences between regions. Both specialists and physicians working 
in primary care can participate in the Twinning. 
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 Protocol 2 (allergists) 
o Only patients who are not registered in the App will be enrolled. 
o  The physician enrolling the user will complete the questionnaire  and will profile his/her 
patient in a computer by answering an online questionnaire (ARIA-EUFOREA website)  
o The physician will end the profile by adding a random alpha-numerical code to his/her patient 
profile (as we process during clinical study). This code will be manually registered by the 
patient on his/her smartphone at the downloading step of the App. 
o Hence, physicians' profile data and patients' self-recorded symptoms data will be reconciled 
for analysis. 
o The physician will ask the person to use the Allergy Diary and will check onsite that this is 
done and that the user has agreed to be geolocalised. 
 Protocol 3: Fit at work: Some enterprises (NHS Northern Ireland, Hôpital de Valenciennes, 
France) are participating in an analysis of work productivity. 
For the three protocols, there is potential for direct benefit for the patients and the physicians.  
As an example, during the patient’s next visit, the physician will see a graph indicating the level of 
control, the compliance to the treatment and the treatments actually taken by the patients.  
Moreover, the first results of the Allergy Diary are extremely interesting (3, 6). Unpublished data 
show that the care pathways of patients with AR and asthma multimorbidity should be reconsidered 
as most patients self-medicate.  
5- Real time analysis of the data. The analysis will be based on the pilot study of the Allergy 
Diary (manuscript submitted and manuscript in preparation) and real time analysis across the 
different Reference Sites will be available. 
4- Expected outcomes of the Twinning activities 
1- Phenotypic characteristics: The Allergy Diary collects information on AR symptoms and allergic 
multi-morbidities experienced (nasal and ocular, asthma), on how symptoms impact users’ lives, 
and on the type(s) of AR and asthma treatments used. The study provides a unique opportunity (i) 
to investigate the phenotype of rhinitis and asthma multimorbidity in the elderly in Europe, (ii) to 
study differences with other age groups using data on file and (iii) to make comparisons across 
countries. 
2- Treatment of rhinitis and asthma multimorbidity and disease control: The control of rhinitis 
appears to differ depending on the age group. The study will show differences (i) with other age 
groups using data on file and (ii) between regions, allowing optimisation of care pathways. 
3- Use of the EQ-5D allows quality-of-life and utilities data to be assessed. It is a MAFEIP tool (39, 
55). 
4- Comparison between regions (or countries depending on the health system) 
5- Comparison between rural and urban environments 
6- Care pathways: the results of the study will be used to develop region-specific care pathways 
(AIRWAYS ICPs) using a personalized medicine approach. Self-management strategies will be of 
great importance. 
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7- Knowledge and know-how transferred. The epidemic wave of rhinitis in adults (over 25% of the 
European population) is now reaching the elderly. It is essential to better characterize, understand 
and manage this disease that affects social life and causes serious discomfort for sufferers. A pan-
European view of the problem will allow a cost-effective and socially acceptable management of 
this disease. The Allergy Diary, developed by the MACVIA France Reference Site, is freely 
available for subjects in most European countries. The app will be deployed by the Reference Site 
Collaborative Network for transfer of knowledge (40, 56).   
8- Rhinitis and asthma multimorbidity exemplify why a lifecourse approach to AHA is the key to 
effective interventions that are sustainable for the public health systems 
5- Future developments 
 Sleep is impaired in rhinitis and asthma (4, 5) and the Allergy Diary has been found to accurately 
assess sleep impairment (6). More data are needed and the App is being improved to include sleep-
related questions.  
 To correlate Allergy Diary data with allergen exposure using classical methods such as pollen 
counts or Google Trends-derived methods (57). 
 To better understand the links between AR and pollution in order to provide preventive and 
treatment strategies to reduce AR burden. 
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Table 1: Objectives of the Twinning 
 
 General objectives: To compare phenotypic characteristics of rhinitis and asthma multimorbidity in 
adults and the elderly using validated ICT tools (Allergy Diary and CARAT) in EIP on AHA Reference Sites 
across Europe to better understand, assess burden, diagnose and manage rhinitis in the elderly. 
 Specific objectives 
1- To assess the percentage of adults and elderly who are able to use the Allergy Diary:  
- Cross-sectional study: The study will include all users recruited by Reference Sites over a period of one 
year. All baseline characteristics will be analysed. Phenotypic characteristics and treatment of rhinitis and 
asthma multimorbidity in the elderly will be compared with those of adults. 
- Longitudinal study: The study will include all users recruited by Reference Sites over a period of one year 
who have reported more than one day of VAS. VAS scores will be analysed. This part of the study may provide 
some insight into the differences between the elderly and adults in terms of response to treatment and 
practice.  
2- To better understand the methodological problems in this new type of observational study, and particularly 
age-dependent problems with ICT. 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2- Complementary activities of the Twinning 
 
 Andalucia will contribute to the mHealth assessment strategy and will test the quality of the mobile health 
App (Allergy Diary) (http://www.calidadappsalud.com/en).  
 Northern Ireland will test another aspect of rhinitis and asthma multimorbidity (fit at work with rhinitis) as 
uncontrolled allergic and non-AR has a major impact on work productivity (2, 41-45). 
 Porto4ageing will also contribute with (i) the implementation of CARAT in the Allergy Diary app for 
European countries with completed cultural adaptation processes (The Netherlands, Belgium, Germany, 
Greece, Ukraine, Italy, France) (25-28) and (ii) the analysis of long-term longitudinal variability of CARAT 
scores and its associations with the MASK VAS. 
 The Region Köln-Bonn will help with the ethical aspects of the Twinning. 
 The Trentino reference site will explore the advocacy of MACVIA study results within the Trentinosalute 
4.0  Competence Centre on digital health. 
 
 
Table 3: Originator and adopters of the Twinning 
Originator 
1.    MACVIA-France  
J Bousquet, S Arnavielhe, A Bedbrook, C Cartier, P Demoly, G Onorato, R Jaquet, D Laune, F Viart 
Adopters   
2. Andalucia 
AM Carriazo, J Ferrero 
3. Aragon 
R Angles 
4. Campania  
M Illario, M Triggiani, C Stellato, A Vatrella, G De Feo 
 
5. Catalonia  
A Dedeu Baraldès, M Olivé Elias, JM Anto, V Cardona, J Mullol, A Valero   
6. City of Helsinki 
T Haahtela, T Strandberg, E Valovirta, J Salimaki, S Toppila-Salmi, J  Karjalainen,  T Vasankari  
7. Coimbra 
J Malva, A Todo Bom, C Robalo-Cordeiro, M Morais Almeida, MT Veríssimo, A Mota-Pinto 
8. Heraklion 
EP Prokopakis 
9. Köln-Bonn Region 
R Mösges, L Klimek, T Bieber, A Zurkuhlen, O Pfaar, T Zuberbier, KC Bergmann 
10. Life Tech Valley 
I Lieten, PW Hellings, C Bachert 
11. Liguria 
G Passalacqua, E Bacci, L Bertorello 
12. Lodz   
P Kuna, M Bochenska-Marciniak, M Kupczyk, P Lacwik 
13. Medical Delta 
NA Guldemond, NH Chavannes, R Gerth van Wijk, WJ Fokkens 
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14. Milan Metropolitan - Bergamo Province 
M Romano, M Sorlini, AC Pozzi, D Lauri, F Corti, G Levato, M Nalin, I Baroni    
15. NHS 24 
A Sheikh, A Custovic 
16. Northern Ireland 
I Young, E Colgan   
17. Olomouc 
V Kolek, Z Gutter, M Sova   
18. Pays de la Loire 
A Magnan, J Hajjam, L Colas 
19. Porto  
J Fonseca, M Costa, AM Pereira    
20. Puglia 
MT Ventura 
21. Regione Piemonte 
C Bucca, G Moda, G Rolla, A Romano, V Tibaldi 
22. Region of Southern Denmark 
C Bindslev-Jensen, E Eller, C Wanscher 
23. Région Nouvelle Aquitaine 
I Bosse 
24. Turkey (Global Alliance against Chronic Respiratory Diseases Regional Network) 
A Yorgancioglu, B Gemicioglu,  C Cingi, O Kalayci, F Kalyoncu 
25. ARIA Sweden 
M Wickman, E Melén 
26. ARIA Lithuania 
A Valiulis, R Dubakiene, R Emuzyte, V Kvedariene 
27. Australia 
SBosnic-Anticevich, RE O’Hehir  
 
28.  Brazil 
AA Cruz 
29. Mexico 
D Larenas-Linnemann 
30. Argentina 
JC Ivancevich 
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Table 4: Questionnaire to be filled in by the physician 
 
 
MACVIA- ARIA  
Physician’s Questionnaire  
 
Date : _ /_/_ 
1- Date of birth  LIST WITH YEARS_ /_/_ 
2- Sex Male Female 
  
3- The patient is suffering from 
Current allergic rhinitis     
Current asthma (within the past 3 months)  
Conjunctivitis  
Non-allergic rhinitis     
Asthma previously in life    
Current atopic dermatitis  
4-  Impact of allergic symptoms 
  Yes No Don't know 
Symptoms affect sleep    
Symptoms restrict daily activities    
Symptoms restrict work or participation in school    
Symptoms are troublesome    
5- CARAT Questionnaire Question 5- A) should be read to the patient with the patient choosing the answer. There should be no 
"interpretation": the physician should not fill in the questionnaire on behalf of the patient. 
A) Due to your allergic respiratory diseases (asthma, rhinitis, allergies) in the last four weeks, on average, how many times did 
you have: 
  
Never 
Up to 2 days per 
week 
More than 2 
days per week 
Almost every 
day  
Blocked nose?     
Sneezing?     
Itchy nose?     
Runny nose?     
Shortness of breath/dyspnoea?     
Wheezing in the chest?     
Chest tightness during physical exercise?     
Tiredness/limitations in doing daily tasks?     
Waking up in the night?     
5- CARAT Questionnaire Question 5- B) should be read to the patient with the patient choosing the answer. There should be no 
"interpretation": the physician should not fill in the questionnaire on behalf of the patient.   
B) Due to your allergic respiratory diseases (asthma, rhinitis, allergies) in the last four weeks, how many times did you:  
  
I’m not taking 
any medicine 
Never Less than 7 days 7 or more days 
Increase the use (dosage or frequency) of your 
medicine?     
6- Allergic sensitization has been diagnosed (within the past 5 years) by:  
Skin test  
Specific IgE  
Skin test + Specific IgE  
Not diagnosed  
7- Positive test for:  
House dust mites    
Alder  
Hazel  
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Grass pollen  
Cypress pollen  
Birch pollen  
Other tree pollen  
Parietaria pollen  
Ragweed pollen  
Cat  
Dog  
Other inhalant allergen  
Food allergen  
Don’t know  
8- Prescribed treatment  
(Scrolling list) Add “no treatment” in the scrolling list 
9- The patient currently receives immunotherapy  for : 
House dust mites    
Alder  
Hazel  
Grass pollen  
Cypress pollen  
Birch pollen  
Other tree pollen  
Parietaria pollen  
Ragweed pollen  
Cat  
Dog  
Other inhalant allergen  
None  
10- Current immunotherapy is administered by: 
SCIT  
SLIT drops  
SLIT tablets  
Oralair  
Grazax  
11- Date of initiation of immunotherapy   
Month/Year (Scrolling list) 
12- Education 
Secondary school or less     
Sixth form or college      
Bachelor degree    
Postgraduate     
Missing   
13- Work Status 
Currently full time employed  
On light duty or some restricted work assignment or part time  
Paid leave/sick leave    
Unemployed because of other reason    
Student (school, college, university)    
Keeping house/homemaker    
Retired    
On disability    
Missing   
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Table 5: Protocols of the Twinning 
 
 Protocol 1 Protocol 2 Protocol 3 
 Short version Long version Fit-at-work 
Allergy Diary + + + 
EQ5D, WP-AIAS Optional + + 
Physician questionnaire  + Optional 
Ethical committee Not needed Obtained Needed if physician’s 
questionnaire 
Participation 
agreement 
Terms of use of 
App 
Participation agreement 
form signed by patients 
 
Recruitment Any user.  Persons 
attending clinic 
visits can be 
included 
Persons with rhinitis from 
clinics with a diagnosis of 
AR made by a specialist 
(with skin tests and/or 
specific IgE) 
Users in settings 
participating in the “fit at 
work” protocol 
 
 
Figure 1: Twinning of the Allergy Diary in EIP on AHA Reference Sites (15-11-2016)  
 
 
 
Country with a Twinning activity                Twinning in the entire country        
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Figure 2: Transfer of patient information on a computer and printed information 
1- Open the Allergy Diary app and choose "Show Data on Computer" in the main menu 
2- Go to www.macvia-aria-allergy-diary.com/data on your PC/Laptop (enter this URL in the address bar of 
the browser from your PC/Laptop) 
3- Scan the QR code with the Allergy Diary app 
4- The screen with your personal data can be seen 
5- And you can also print these data (see figure below). 
 
 
 
 
 
 
